About Us
Innovative Drugs
Innovation Platform
News
Join Us
Contact Us
Keyword:
Latest News
Jiangsu Vcare Announces Positive Phase II Results for VC005 Topical Gel, a Second-Generation Highly Selective JAK1 Inhibitor, in the Treatment of Mild-to-Moderate Atopic Dermatitis (AD)
Jiangsu Vcare’s Next-Generation TRK Inhibitor Eratrectinib (VC004) Selected for the “SPARK Plan” for Pediatric Oncology Drugs
Jiangsu Vcare Announces First Patient Enrollment in Phase Ⅱ Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor, for Oral Treatment of Vitiligo
Jiangsu Vcare Completes Phase III Enrollment of VC005, a Next-Generation High-Selective JAK1 Inhibitor for Moderate-to-Severe Atopic Dermatitis
Jiangsu Vcare Launches Phase III Clinical Trial of VC005, a Highly Selective JAK1 Inhibitor, for Ankylosing Spondylitis
Jiangsu Vcare Initiates Phase II Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor, for Oral Treatment of Vitiligo